The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This three-group randomized double-blind placebo-controlled trial (N=180) will evaluate the
impact of combination zonisamide and bupropion on the process of switching from combustible
cigarettes (CCs) to an e-cigarette. There will be a data collection period of at least five
days to obtain baseline information on the use of combustible cigarettes. All participants
enrolled in the study will receive a JUUL e-cigarette at Visit 2 for ad libitum use. After
the first week of e-cigarette use (at Visit 3), participants will be given bupropion (150 mg
each morning for days 1-3, then 300 mg daily) with either zonisamide (100 mg daily) or
placebo (group 1 and group 2 respectively), or placebo for both medications (group 3) in
addition to continued use of the e-cigarette. At each visit, participants will receive enough
study drugs (or placebos) and e-cigarettes to last until their next study visit. The
combination of zonisamide and bupropion use will continue until Visit 6 (7 weeks of
treatment), and e-cigarette use will continue until the end of treatment (Visit 7).